All In Biotech

Drug Trial Radar · NCT05212246

Basal Cell Carcinoma Chemoprevention Trial

CSP #2019 - Basal Cell Carcinoma Chemoprevention Trial (B3C)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,630 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,630

Planned (sponsor's estimate)

Start

Oct 6, 2026

Primary completion

Oct 6, 2032

Study completion Oct 6, 2032

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Jan 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.

Conditions

  • Basal Cell Carcinoma

Interventions

  • 5% Imiquimod creamDrug

    Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.

  • Placebo Vehicle Control CreamDrug

    The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with a new Basal Cell Carcinoma (BCC) on the face at 1 yearTime frame: 1 year from the time of randomization
  2. Basal Cell Carcinoma (BCC) free time to a new BCC on the face over 3 yearsTime frame: 3 years from the time of randomization

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • VA Long Beach Healthcare System, Long Beach, CA

    Long Beach, California · Recruiting

  • VA San Diego Healthcare System, San Diego, CA

    San Diego, California · Recruiting

  • Bay Pines VA Healthcare System, Pay Pines, FL

    Bay Pines, Florida · Recruiting

  • Minneapolis VA Health Care System, Minneapolis, MN

    Minneapolis, Minnesota · Recruiting

  • Durham VA Medical Center, Durham, NC

    Durham, North Carolina · Recruiting

  • Providence VA Medical Center, Providence, RI

    Providence, Rhode Island · Not yet recruiting

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah · Recruiting

  • Clement J. Zablocki VA Medical Center, Milwaukee, WI

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.